The Heart Disease Study of Semaglutide in Patients with Type 2 Diabetes (SOUL) is a more extensive and extended phase 3 CVOT presently being conducted, and results are expected in 2024 [55]
They can only give guidelines
Lifestyle programs without diagnoses will not qualify
Prior authorization requires the provider to get approval from the payer before prescribing the given treatment, typically done by payers to ensure that a given treatment is medically necessary and covered
For patients whose insurance wont cover GLP-1 medications, lower-cost compounded versions can seem like an attractive alternative, but the researchers urge caution
Des-fluoro-sitagliptin (200 mg/kg/day) treatment reduced atherosclerotic lesion formation, infiltration of macrophage and T lymphocytes, and the expression of proinflammatory cytokines within plaques in ApoE / mice [68]